A Letter from GCMI Interim Executive Director Saylan Lukas – GCMI’s Continuing Commitment to Excellence in Medtech Innovation

Medtech and life science innovation is rigorous. It requires high levels of acumen and proficiency in multiple disciplines. It can also be immensely capital intensive. Tiffany Wilson founded Atlanta’s Global Center for Medical Innovation (GCMI) in 2012 to help medtech innovators de-risk their technologies, increasing their odds of successful commercialization and positive patient outcomes within…

Read More

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid Requirement

Atlanta, GA, January 29, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the Company’s Board of Directors has approved a reverse stock split of its issued and outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), at a…

Read More

Aruna Bio Announces FDA Clearance of IND for Lead Program AB126, Enabling the First Exosome to Enter in Human Clinical Trials for a Neurological Indication

January 16, 2024 08:00 ET| Source: Aruna Bio BOSTON and ATHENS, Ga., Jan. 16, 2024 (GLOBE NEWSWIRE) — Aruna Bio, Inc., a pioneer in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application of lead program,…

Read More

GeoVax Announces Issuance of Malaria Vaccine Patent

Patent Covers Multiple Component Vaccine for Both Prevention and Treatment Atlanta, GA, January 3, 2024 – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,857,611 to GeoVax, pursuant to the Company’s patent application No.…

Read More

SIRPant Immunotherapeutics Announces FDA Clearance of IND Application for SIRPant-MTM for the Treatment of Solid Tumors

HUMMELSTOWN, Pa., Dec. 12, 2023 (GLOBE NEWSWIRE) — SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application for the Company’s lead product candidate, SIRPant-M™,…

Read More

Micron Biomedical Receives $23.6 Million to Accelerate Commercial Manufacturing of Needle-Free Vaccines and to Help Eradicate Measles

November 16, 2023 November 16 2023, ATLANTA– Micron Biomedical, a life science company developing first-in-class dissolvable microarray-based products that simplify and improve the transport, storage, and administration of drugs and vaccines, today announced a $23.6 million grant from the Bill & Melinda Gates Foundation that will fund mass production of needle-free vaccines.  The manufacturing facility will…

Read More

Life Science Nation bringing a medtech investor event to Atlanta in early 2024

In September, Life Science Nation announced “RESI South’ in partnership with a newly formed coalition of life science associations representing Alabama, Florida, Georgia, North Carolina, South Carolina, Tennessee, and Virginia. The conference will come to Atlanta, GA, in [early] 2024. RESI South is expected to draw a crowd of over 500 bioscience and medtech entrepreneurs…

Read More